Cite
HARVARD Citation
Haddad, R. et al. (2019). Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 125 (18), pp. 3208-3218. [Online].